Tissue | Expression Dynamics | Abbreviation |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/GAS6_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/GAS6_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/GAS6_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/GAS6_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/GAS6_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007135615 | Endometrium | EEC | cellular response to tumor necrosis factor | 45/2168 | 229/18723 | 2.54e-04 | 2.94e-03 | 45 |
GO:003320912 | Endometrium | EEC | tumor necrosis factor-mediated signaling pathway | 24/2168 | 99/18723 | 3.12e-04 | 3.47e-03 | 24 |
GO:004682515 | Endometrium | EEC | regulation of protein export from nucleus | 11/2168 | 30/18723 | 3.27e-04 | 3.61e-03 | 11 |
GO:004682214 | Endometrium | EEC | regulation of nucleocytoplasmic transport | 25/2168 | 106/18723 | 3.71e-04 | 3.97e-03 | 25 |
GO:005109013 | Endometrium | EEC | regulation of DNA-binding transcription factor activity | 75/2168 | 440/18723 | 3.71e-04 | 3.97e-03 | 75 |
GO:003461215 | Endometrium | EEC | response to tumor necrosis factor | 48/2168 | 253/18723 | 3.77e-04 | 4.03e-03 | 48 |
GO:00017641 | Endometrium | EEC | neuron migration | 33/2168 | 156/18723 | 4.17e-04 | 4.38e-03 | 33 |
GO:00447641 | Endometrium | EEC | multi-organism cellular process | 7/2168 | 14/18723 | 4.53e-04 | 4.69e-03 | 7 |
GO:001046615 | Endometrium | EEC | negative regulation of peptidase activity | 49/2168 | 262/18723 | 4.64e-04 | 4.79e-03 | 49 |
GO:005189712 | Endometrium | EEC | positive regulation of protein kinase B signaling | 27/2168 | 120/18723 | 4.93e-04 | 5.01e-03 | 27 |
GO:000268513 | Endometrium | EEC | regulation of leukocyte migration | 41/2168 | 210/18723 | 5.35e-04 | 5.38e-03 | 41 |
GO:001095114 | Endometrium | EEC | negative regulation of endopeptidase activity | 47/2168 | 252/18723 | 6.37e-04 | 6.25e-03 | 47 |
GO:005087816 | Endometrium | EEC | regulation of body fluid levels | 65/2168 | 379/18723 | 7.48e-04 | 7.05e-03 | 65 |
GO:006032613 | Endometrium | EEC | cell chemotaxis | 55/2168 | 310/18723 | 8.22e-04 | 7.63e-03 | 55 |
GO:003166916 | Endometrium | EEC | cellular response to nutrient levels | 41/2168 | 215/18723 | 8.72e-04 | 7.97e-03 | 41 |
GO:003059513 | Endometrium | EEC | leukocyte chemotaxis | 43/2168 | 230/18723 | 1.01e-03 | 8.89e-03 | 43 |
GO:003210313 | Endometrium | EEC | positive regulation of response to external stimulus | 71/2168 | 427/18723 | 1.06e-03 | 9.18e-03 | 71 |
GO:004315410 | Endometrium | EEC | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process | 19/2168 | 78/18723 | 1.19e-03 | 1.00e-02 | 19 |
GO:003166816 | Endometrium | EEC | cellular response to extracellular stimulus | 45/2168 | 246/18723 | 1.24e-03 | 1.03e-02 | 45 |
GO:000268813 | Endometrium | EEC | regulation of leukocyte chemotaxis | 26/2168 | 122/18723 | 1.45e-03 | 1.18e-02 | 26 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GAS6 | SNV | Missense_Mutation | | c.870N>C | p.Lys290Asn | p.K290N | Q14393 | protein_coding | deleterious(0) | possibly_damaging(0.769) | TCGA-C8-A132-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GAS6 | SNV | Missense_Mutation | rs146140804 | c.1211N>T | p.Ala404Val | p.A404V | Q14393 | protein_coding | tolerated(0.99) | benign(0.277) | TCGA-E2-A1IH-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | aromasin | SD |
GAS6 | SNV | Missense_Mutation | rs748222907 | c.337N>A | p.Val113Met | p.V113M | Q14393 | protein_coding | deleterious(0) | possibly_damaging(0.905) | TCGA-GM-A4E0-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | xeloda | CR |
GAS6 | deletion | Frame_Shift_Del | | c.449delG | p.Gly150AlafsTer49 | p.G150Afs*49 | Q14393 | protein_coding | | | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GAS6 | insertion | Frame_Shift_Ins | rs773341392 | c.449_450insG | p.Arg151ProfsTer27 | p.R151Pfs*27 | Q14393 | protein_coding | | | TCGA-B6-A0RE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GAS6 | SNV | Missense_Mutation | novel | c.1921C>T | p.Arg641Cys | p.R641C | Q14393 | protein_coding | deleterious(0.01) | possibly_damaging(0.786) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
GAS6 | SNV | Missense_Mutation | novel | c.1297C>A | p.Leu433Ile | p.L433I | Q14393 | protein_coding | deleterious(0.03) | probably_damaging(0.998) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
GAS6 | SNV | Missense_Mutation | rs771931132 | c.1163C>T | p.Ala388Val | p.A388V | Q14393 | protein_coding | deleterious(0.01) | benign(0.045) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
GAS6 | SNV | Missense_Mutation | | c.302N>G | p.Ser101Cys | p.S101C | Q14393 | protein_coding | deleterious(0.03) | possibly_damaging(0.642) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
GAS6 | SNV | Missense_Mutation | | c.803T>A | p.Leu268His | p.L268H | Q14393 | protein_coding | tolerated(0.13) | probably_damaging(0.912) | TCGA-EA-A5O9-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |